ADPT — Adaptive Biotechnologies Corpor

Is ADPT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of July 5, 2026

Adaptive Biotechnologies Corpor (ADPT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Diagnostics & Research) last closed at $21.19. The rating moved from Neutral to Overbought on July 3, 2026 and has changed 12 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$21.19
Rating changesRating changed 12 times in the last 90 days
Last changeMoved from Neutral to Overbought on July 3, 2026
SectorHealthcare
IndustryDiagnostics & Research

Latest MarketMoodz coverage

Adaptive Biotechnologies Eyes Split of MRD and Immune Medicine2026-06-16

See today's live rating, score and targets

Members see the live hourly rating for ADPT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.